Herceptin (trastuzumab)

Pertuzumab numerically improved IDFS in all subgroups, greatest in HER2 FISH-low/ER-positive tumors. These exploratory findings are hypothesis-generating and support prospective validation of biomarker-guided strategies.

Evaluation of cell death using the WST-8 assay also demonstrated a significantly higher cytotoxic effect of G-Ce6-trastuzumab in HER2-high-expression cells compared with conventional PS G-Ce6. Thereby, G-Ce6-trastuzumab may be an excellent novel PS for PDT because of its strong selectivity for HER2-high-expression cells.

In this research report, we designed NIR-responsive Fe3O4@MIL-100(Fe)-Upconversion nanoparticles (FMUNPs) functionalized injectable β-cyclodextrin/hyaluronic acid macromolecular hydrogel-encapsulated with HER-2 targeting trastuzumab (TZB) molecules to induce ROS against gastric cancer cells...In-vivo study demonstrated that the significant reduction on tumor volume and size when tumor-induced mice treated with developed formulation with NIR irradiation. This investigation outcome demonstrates this novel formulation could be a new avenue for the gastric cancer treatment.

P2, N=393, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Mar 2026

Tet2-deficient mice demonstrated a significant LVEF reduction following trastuzumab treatment (effect size, -4.2%; 95% CI, -7.91 to -0.49; P = .03); other experimental groups showed no significant change. In this cohort study, the presence of CHIP was associated with increased susceptibility to trastuzumab-related cardiotoxic effects.

IT trastuzumab in combination with GM-CSF is safe in recurrent pediatric PF EPN. A larger phase 2 study that includes both recurrent PFA and RELA-ST EPN is needed to determine the long-term efficacy of this immunotherapy strategy.

P2, N=189, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026

P1/2, N=1000, Recruiting, DualityBio Inc. | Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Dec 2027

P2, N=20, Recruiting, Xiujuan Qu

Our approach demonstrates enhanced efficacy compared to the combination of trastuzumab and bevacizumab in xenograft models. This bispecific degradation strategy serves as a valuable therapeutic modality for the simultaneous depletion of both membrane-bound and secreted proteins. Furthermore, its modular design makes this dual-target degradation technology readily adaptable to other disease-relevant extracellular antigen pairs.

Our patient presented with a visceral crisis denoted by impending liver failure, prompting the urgent initiation of first-line systemic therapy with fluorouracil, leucovorin, oxaliplatin and trastuzumab. This resulted in rapid clinical improvement, normalisation of liver function tests and tumour markers, and radiographic response with approximately 50% reduction in hepatic metastatic disease burden. This case underscores the aggressive behaviour and rarity of HER2-positive, AFP-producing gastric cancer, highlighting the critical need for prompt diagnosis and initiation of systemic therapy.

DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies.